S&P 500 Futures
(0.00%) 5 478.25 points
Dow Jones Futures
(-0.04%) 38 804 points
Nasdaq Futures
(0.05%) 19 931 points
Oil
(0.27%) $80.55
Gas
(1.18%) $2.82
Gold
(0.17%) $2 333.00
Silver
(-0.28%) $29.31
Platinum
(-0.12%) $969.70
USD/EUR
(0.02%) $0.932
USD/NOK
(-0.14%) $10.64
USD/GBP
(0.07%) $0.788
USD/RUB
(-1.87%) $86.80

Realaus laiko atnaujinimai CytomX Therapeutics Inc [CTMX]

Birža: NASDAQ Sektorius: Healthcare Pramonė: Biotechnology
Atnaujinta17 birž. 2024 @ 23:00

-0.72% $ 1.370

Live Chart Being Loaded With Signals

Commentary (17 birž. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.94% compare to its pairs and should correct upwards.
Profile picture for CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer...

Stats
Šios dienos apimtis 1.59M
Vidutinė apimtis 6.64M
Rinkos kapitalizacija 106.75M
EPS $0.170 ( Q1 | 2024-05-08 )
Kita pelno data ( $0 ) 2024-08-06
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 6.52
(Sector) 42.63
(Industry) 24.32
ATR14 $0.00500 (0.36%)
AADI -3.55%
ABCL -5.26%
ABCM 0.04%
ABEO -1.31%
ABIO -1.53%
ABOS -5.30%
ABSI -14.32%
ABUS -2.55%
ABVX -0.22%
ACAD -0.47%
ACER -17.95%
ACET -2.22%
ACGN 1.29%
ACHL 0.23%
ACHV 1.63%
ACIU -4.23%
ACLX -1.21%
ACRV -5.10%
ACST 0.62%
ACXP -0.42%
ADAG -5.64%
ADAP -7.23%
ADGI 0.87%
ADIL -2.29%
ADMA -1.79%
ADPT 0.32%
ADTX -7.69%
ADVM -3.94%
ADXN -6.11%
AEON 11.51%
AEZS -5.44%
AFMD -5.07%
AGEN -7.50%
AGIO -3.45%
AGLE 6.66%
AGTC 0.00%
AIKI 0.85%
AIMDW 53.45%
AKBA -1.87%
AKRO -4.46%
AKTX -6.33%
AKUS 0.00%
ALBO 0.00%
ALDX -1.34%
ALEC -2.35%
ALGS -5.76%
ALKS 2.08%
ALLK 0.86%
ALLO -2.13%
ALLR -3.01%
ALNA 3.16%
ALNY -1.93%
ALPN 0.00%
ALPX 0.00%
ALRN -0.31%
ALT -3.11%
ALVR -4.43%
ALXN 0.00%
ALXO -8.32%
ALZN -12.01%
AMRN -2.58%
AMTI -3.13%
ANAB -1.64%
ANEB -5.58%
ANGN 0.00%
ANIX -0.38%
ANL 0.61%
ANNX -4.63%
ANPC -3.15%
APGE -5.23%
APGN 8.48%
APGNW 30.65%
APLM -4.73%
APLS -3.98%
APLT -4.36%
APM 1.33%
APOP 0.38%
APRE 2.44%
APTO -3.96%
APTX 3.17%
APVO -20.53%
ARAV -13.39%
ARCT -9.26%
ARDS 20.48%
ARDX -0.94%
ARGX -2.25%
ARNA 0.00%
ARPO -0.90%
ARQT -7.76%
ARTL -0.38%
ARTLW 9.80%
ARVN -2.84%
ARWR -2.86%
ASLN -12.17%
ASMB -1.49%
ASND -2.39%
ATAI -2.19%
ATHA 2.36%
ATHE -1.61%
ATHX -33.50%
ATNF 15.09%
ATOS -4.17%
ATRA -16.93%
ATXI -1.66%
ATXS -3.50%
AUPH -1.95%
AURA 0.96%
AUTL -4.22%
AVBP -1.02%
AVEO 0.00%
AVIR -2.22%
AVRO 2.10%
AVTE -93.30%
AVTX 4.08%
AVXL -1.06%
AXLA 0.00%
AXSM 3.22%
AYLA 0.00%
AZRX 2.07%
BBI 2.17%
BBIO -2.26%
BCAB -1.89%
BCDA -2.05%
BCDAW -33.33%
BCEL -1.32%
BCLI -8.47%
BCRX 1.13%
BCTX 4.96%
BCTXW 0.00%
BCYC -4.33%
BDRX 1.89%
BDTX -8.38%
BEAM -3.38%
BFRA -2.91%
BGNE -1.97%
BIOR -10.12%
BIVI 0.41%
BLCM -6.68%
BLI -5.88%
BLPH -0.79%
BLRX -3.79%
BLTE -0.72%
BLU 0.03%
BLUE -0.77%
BMEA -9.75%
BMRN 1.81%
BNOX 1.64%
BNTC 2.46%
BNTX -3.95%
BOLD -5.95%
BOLT -0.82%
BPMC -1.59%
BPTH 10.65%
BPTS -13.47%
BRNS -6.63%
BRTX 20.00%
BTAI -2.92%
BTTX -7.50%
BTX 0.05%
BVXV 0.74%
BXRX 7.39%
BYSI 6.06%
CABA -12.20%
CADL -0.96%
CALA 60.00%
CALC -1.62%
CALT 0.03%
CAPR -4.06%
CARA -27.26%
CARM -9.65%
CASI -8.04%
CATB -6.97%
CBAY 0.03%
CBIO -2.65%
CBLI -7.31%
CBUS 3.07%
CCCC -5.48%
CCXI 0.00%
CDAK 0.00%
CDIO -1.51%
CDIOW -23.08%
CDMO 5.72%
CDMOP 0.04%
CDT -6.11%
CDTTW -47.71%
CDTX -6.32%
CDXC -0.67%
CDXS -2.30%
CELC -2.79%
CELU -2.19%
CELUW -9.52%
CERC -1.68%
CERE -0.16%
CERO -7.87%
CEROW -44.78%
CFRX -27.95%
CGEM 0.74%
CGEN -5.31%
CGON -2.68%
CGTX 0.92%
CHMA -6.00%
CHRS -2.96%
CINC 0.00%
CING -1.09%
CINGW -48.24%
CKPT -4.25%
CLBS -16.75%
CLDX 0.69%
CLGN 1.19%
CLLS -4.89%
CLNN -2.48%
CLNNW -41.25%
CLRB -9.94%
CLSD -0.84%
CLSN -0.68%
CLVS 0.00%
CMMB -24.79%
CMND 1.83%
CMPI 0.00%
CMPX 5.41%
CMRA 0.40%
CMRAW 33.33%
CMRX 1.44%
CNCE 0.00%
CNSP 3.94%
CNST 0.00%
CNTA -6.39%
CNTB 3.13%
CNTX -1.02%
COCP -0.16%
COEPW -0.66%
COGT 4.45%
CORT -1.31%
COYA -6.11%
CPRX -0.40%
CRBP -11.76%
CRBU -2.23%
CRDF -1.11%
CRGX -4.78%
CRIS 1.11%
CRNX -1.37%
CRSP -2.79%
CRTX 2.63%
CRVO -1.89%
CRVS -5.39%
CSBR 1.19%
CTCX -8.04%
CTIC 0.06%
CTMX -0.72%
CTNM 0.00%
CTXR -1.50%
CUE -1.47%
CVAC -5.18%
CVKD 3.18%
CWBR -2.55%
CYAD -12.96%
CYCC -3.55%
CYCCP -1.79%
CYCN 6.00%
CYT -2.27%
CYTK -2.13%
CYTO 2.48%
DARE -3.31%
DAWN -4.60%
DBTX -0.81%
DBVT 1.01%
DFFN 10.28%
DICE 0.06%
DMAC -0.42%
DNLI -1.21%
DNTH -2.85%
DOMH 1.99%
DRMA 0.00%
DRMAW 0.00%
DRNA 0.00%
DRTS -1.32%
DRTSW 1.01%
DRUG 0.00%
DSGN 2.97%
DTIL -2.07%
DYAI -5.29%
EARS -1.77%
EDIT 0.20%
EDSA 1.04%
EFTR -3.13%
EFTRW -0.26%
EIGR 0.00%
ELAB 1.44%
ELDN -6.93%
ELEV -7.89%
ELOX -12.50%
ELTX -2.33%
ELVN -0.65%
ELYM -13.05%
ENGN -3.89%
ENGNW -7.06%
ENLV -3.47%
ENOB 1.79%
ENSC -0.55%
ENTA -6.00%
ENTO -2.80%
ENTX 0.00%
ENVB -4.64%
EPIX -8.75%
EPRX -0.19%
EPZM 0.00%
EQ 0.50%
EQRX -2.09%
EQRXW 0.00%
ERAS -7.83%
ERNA 2.60%
ERYP 1.30%
ESLA -6.38%
ESLAW -9.25%
ETNB 1.03%
ETON -5.90%
ETTX 0.00%
EVAX -19.54%
EVGN -2.14%
EVLO 50.00%
EWTX -0.80%
EXAI 1.19%
EXEL 0.18%
EYEG -0.43%
EYEN 1.57%
EYPT -3.94%
FATE -1.11%
FBIO 1.60%
FBIOP -1.05%
FBLG -5.34%
FBRX -7.46%
FDMT 0.72%
FENC 0.74%
FGEN -5.36%
FHTX 9.52%
FIXX 0.77%
FMTX 0.00%
FNCH -6.25%
FOLD -0.99%
FREQ 4.76%
FRLN 0.15%
FRTX -0.54%
FSTX 0.00%
FTRE 0.38%
FULC -6.04%
FUSN 0.00%
FWBI 4.59%
FWP 0.00%
GALT -4.58%
GANX 6.45%
GBIO 6.57%
GBT 0.01%
GDTC 2.16%
GERN -4.11%
GHRS 3.42%
GLMD -6.66%
GLPG 1.18%
GLSI 18.16%
GLTO -4.90%
GLUE -4.18%
GLYC -9.70%
GMAB -1.57%
GMDA 0.00%
GMTX 0.00%
GNCA -85.71%
GNFT 0.14%
GNLX 1.27%
GNPX 1.84%
GNTA -0.60%
GOSS 0.02%
GOVX -7.50%
GOVXW -24.72%
GPCR 0.85%
GRAY -10.80%
GRCL 0.05%
GRNA -0.03%
GRNAW 8.91%
GRPH -2.75%
GRTS -2.71%
GRTX -4.26%
GTHX -3.96%
GUTS -3.90%
GXGXW 41.67%
GYRE 4.44%
HALO 0.32%
HARP 0.09%
HCWB -9.73%
HEPA -6.36%
HGEN -84.62%
HILS 5.66%
HLVX 1.33%
HOOK -4.04%
HOTH -3.73%
HOWL 3.99%
HRMY 1.10%
HRTX -10.42%
HSTO 62.16%
HUMA -12.20%
HUMAW -5.97%
IBRX -2.18%
ICCC 2.84%
ICPT 0.21%
ICU 1.30%
ICUCW -10.39%
ICVX -0.91%
IDRA -23.04%
IDYA -1.44%
IFRX -3.21%
IGMS 0.41%
IKNA -0.57%
IKT 8.90%
IMAB -1.09%
IMCR -3.82%
IMGN 0.02%
IMGO 0.00%
IMMP -0.74%
IMMX -0.49%
IMNM -11.86%
IMNN -1.80%
IMPL -27.27%
IMRA 15.96%
IMRN -2.78%
IMRX 1.66%
IMTX -0.08%
IMTXW -2.70%
IMUX -4.20%
IMV 0.00%
IMVT 3.08%
INAB -8.26%
INBX -9.62%
INCY 0.93%
INDP 7.98%
INFI -52.38%
INKT -1.05%
INM -2.58%
INMB -2.47%
INO -1.65%
INSM 1.22%
INTS -5.63%
INVA 1.57%
INZY -2.95%
IOBT -6.11%
IONS 0.27%
IOVA -0.98%
IPA 0.48%
IPHA -10.64%
IPSC 0.64%
IRON -3.05%
ISEE 0.38%
ITOS -6.04%
ITRM -1.74%
IVA -10.10%
IVVD -6.96%
JAGX -6.67%
JANX -4.57%
JAZZ 1.43%
JNCE 0.00%
JSPR -2.80%
JSPRW 2.33%
JUNS 0.00%
JUNSW 0%
KA 4.11%
KALV -2.07%
KDNY 0.22%
KMPH -0.34%
KNSA -1.28%
KNTE -0.38%
KOD -4.27%
KPRX -21.08%
KPTI 1.69%
KRBP 4.17%
KRON -3.70%
KROS -9.68%
KRRO -16.54%
KRTX 0.03%
KRYS -0.04%
KTRA -2.35%
KTTA -2.85%
KTTAW 8.62%
KURA -0.62%
KYMR -4.42%
KYTX -17.21%
KZIA -1.29%
KZR -2.71%
LABP 0.57%
LBPH 1.67%
LBPS 0.00%
LBPSW 14.81%
LEGN -2.24%
LENZ -0.54%
LEXX -5.18%
LEXXW -9.42%
LGND 0.72%
LGNDV 0.00%
LGVN -24.76%
LIAN 0.00%
LIFE 2.70%
LIPO -1.23%
LIXT 0.40%
LIXTW 27.74%
LJPC -0.32%
LMNL 0.12%
LOGC 2.76%
LPCN 12.64%
LPTX -1.90%
LQDA 3.01%
LRMR -14.91%
LSTA -4.97%
LTRN -8.57%
LUMO -2.95%
LVTX -9.52%
LXEO -6.50%
LXRX -5.49%
LYEL -8.05%
LYRA -8.37%
MACK 0.00%
MBIO 476.92%
MBRX -4.83%
MCRB -5.28%
MDGL -0.31%
MDNA -13.16%
MDWD 1.00%
MDXG 0.59%
MEIP 1.41%
MESO -0.55%
MGNX -4.03%
MGTA -7.74%
MGTX -2.23%
MGX -24.14%
MIRM 27.31%
MIRO 0.59%
MIST -1.42%
MITO 0.00%
MLEC -4.55%
MLECW 9.20%
MLND -5.36%
MLTX -2.99%
MLYS -3.02%
MNKD -1.04%
MNMD -3.36%
MNOV 0.00%
MNPR -8.51%
MOLN 8.81%
MOR 0.88%
MORF -1.25%
MREO 0.00%
MRKR 16.59%
MRNA -1.52%
MRNS -1.02%
MRSN -1.45%
MRTX -0.17%
MRUS -1.38%
MRVI -3.99%
MTCR -1.29%
MTEM 1.54%
MTP -18.50%
MURA 2.17%
MYMD 4.19%
NAMS -7.03%
NAMSW -7.61%
NAUT 0.00%
NBRV 0.71%
NBSE -1.56%
NBTX 4.77%
NCNA -1.64%
NERV 8.96%
NEXI 0.00%
NGM -1.28%
NGNE -6.08%
NKGN -4.44%
NKGNW 39.76%
NKTR 0.00%
NKTX -5.66%
NLSP 30.09%
NLSPW -16.67%
NMRA -4.09%
NMTR -42.97%
NOVN -24.84%
NRBO 0.45%
NRIX 0.72%
NRSN -3.82%
NRSNW 6.50%
NRXP 0.99%
NRXPW -15.65%
NRXS -6.06%
NTBL 13.82%
NTEC -12.45%
NTHI 0%
NTLA 0.08%
NTRBW -6.25%
NUVL -0.77%
NVAX -2.43%
NVCT 1.18%
NVIV -34.28%
NXTC -10.63%
NYMX -0.05%
OABI 0.95%
OABIW 13.46%
OBIO 0.88%
OBSV 0.00%
OCEA 10.64%
OCGN -5.63%
OCS -1.09%
OCUL -4.35%
OCUP 1.82%
ODT -4.27%
OKYO 0.00%
OLMA -3.96%
OMER -0.49%
OMGA -8.37%
ONCO 12.54%
ONCR -3.08%
ONCS 31.87%
ONCT -0.12%
ONCY -0.98%
ONTX -0.47%
ONVO 0.62%
OPNT 0.00%
OPT -5.51%
ORGS -1.72%
ORIC -0.67%
ORMP -0.44%
ORPH 0.00%
ORTX 0.30%
OSMT -1.77%
OTIC -92.64%
OTLK -1.43%
OVID -76.00%
OYST 0.00%
PALI 0.86%
PASG -3.81%
PBLA 9.76%
PBM -0.02%
PBYI 2.89%
PCSA 5.71%
PCVX -1.45%
PDSB -4.13%
PEPG 0.70%
PGEN 0.00%
PHAR 2.17%
PHAS 0.00%
PHAT 3.08%
PHIO 4.14%
PHIOW 36.47%
PHVS -0.53%
PHXM -5.20%
PIRS -5.64%
PKBO 0.00%
PKBOW 999 900.00%
PLRX -5.08%
PLUR 0.00%
PMN -5.59%
PMVP -1.20%
PNT 0.16%
PPBT -11.48%
PRAX -6.21%
PRDS 0.93%
PRLD 0.77%
PROG -3.47%
PROK 6.96%
PRQR -3.41%
PRTA -0.20%
PRTC -0.72%
PRTG -1.96%
PRTK 1.83%
PRVB 0.00%
PSTI -2.91%
PSTV 0.00%
PSTX 1.81%
PTCT -1.14%
PTE -0.82%
PTGX -2.76%
PTIXW 2.50%
PULM 3.72%
PXMD -1.92%
PYPD -0.36%
PYXS -3.43%
QLGN -11.72%
QNCX 0.00%
QNRX -10.97%
QSI -2.92%
QSIAW 0.00%
QTTB 3.82%
QURE -4.09%
RAIN -1.63%
RANI -5.46%
RAPT -0.30%
RARE 1.92%
RCKT -3.02%
REGN 0.85%
RENB -3.05%
REPL -6.63%
RETA 0.02%
REUN -0.89%
REVB 1.36%
REVBU 3.46%
REVBW 25.20%
RGLS -1.66%
RGNX -6.20%
RIGL -2.79%
RLAY -3.01%
RLMD -0.33%
RLYB -6.15%
RNA -0.10%
RNAC -14.55%
RNAZ -5.83%
RNXT 14.41%
ROIV 0.28%
ROIVW 4.56%
RPHM -0.60%
RPRX -1.15%
RPTX 0.00%
RUBY 2.70%
RVLP -32.05%
RVMD -3.94%
RVMDW -23.93%
RVNC -0.71%
RVPH -0.68%
RVPHW 11.54%
RXDX 0.09%
RXRX 1.19%
RYTM -3.76%
RYZB 0.02%
RZLT -2.53%
SABS 3.17%
SABSW -32.14%
SAGE -6.08%
SANA -1.32%
SAVA 0.81%
SAVAW 0.00%
SBBP 1.52%
SBTX 1.03%
SCNI 60.46%
SCPH -1.69%
SCPS 0.00%
SEEL -4.62%
SEER -3.37%
SELB -8.00%
SESN 7.29%
SGEN -0.07%
SGMO -17.30%
SGMT 1.93%
SGTX -2.56%
SIOX 22.63%
SLDB -5.44%
SLGL -2.22%
SLN -1.55%
SLNO 0.19%
SLRX 2.89%
SLS -16.67%
SMMT -5.84%
SNDX -1.14%
SNGX -5.91%
SNPX -3.97%
SONN -4.75%
SPPI -0.49%
SPRB 0.49%
SPRC -3.16%
SPRO -5.88%
SRNE 20.00%
SRPT -4.89%
SRRA 0.00%
SRRK -7.09%
SRZN -1.70%
STAB 0.00%
STOK -4.00%
STRO -7.51%
STSA 0.00%
STTK -19.55%
SURF -0.93%
SVRA -5.15%
SWTX -4.88%
SYBX -0.63%
SYRS -4.83%
TALS -0.73%
TARA -0.78%
TARS -6.91%
TBPH -0.59%
TCBP -8.64%
TCDA 0.00%
TCON 6.35%
TCRR 0.00%
TCRT 1.05%
TCRX -11.43%
TECH -1.40%
TENX -3.43%
TERN -2.93%
TFFP 0.52%
TGTX 0.12%
THRX 0.12%
TIL -2.06%
TLC 0.00%
TLSA 5.78%
TNGX 5.04%
TNXP -2.61%
TNYA -1.79%
TPST 0.34%
TRDA -3.61%
TRVI 2.08%
TRVN -1.88%
TSHA 1.51%
TSVT 3.29%
TTNP 1.45%
TVTX 2.23%
TYRA -8.69%
UBX -4.17%
UNCY 0.22%
URGN -4.79%
UTHR 3.12%
VACC 11.36%
VALN -1.55%
VAXX -0.11%
VBIV -3.61%
VBLT -8.77%
VCEL -1.37%
VCNX -3.70%
VCYT 1.96%
VERA -0.83%
VERU 2.29%
VERV -2.77%
VIGL -2.08%
VINC -4.90%
VIR -5.85%
VIRI 4.95%
VIRX -3.62%
VKTX 0.00%
VLON -13.04%
VNDA 1.76%
VOR 1.74%
VRCA 0.49%
VRDN -1.93%
VRNA 10.04%
VRPX 10.77%
VRTX -1.46%
VSTM 0.00%
VTGN -2.84%
VTVT -0.10%
VTYX -4.51%
VXRT -8.25%
VYGR -2.94%
VYNE 2.16%
VYNT 7.78%
WINT 7.98%
WVE -3.85%
XBIO 6.75%
XBIT -0.33%
XCUR -3.10%
XENE -1.75%
XERS -0.91%
XFOR -2.75%
XLO -6.86%
XLRN 0.00%
XNCR -5.15%
XOMA -4.31%
XOMAO 0.68%
XOMAP -0.14%
XRTX 1.96%
YMAB -1.34%
ZGNX 0.00%
ZIOP -0.88%
ZLAB 1.55%
ZNTL -5.09%
ZSAN 0.00%
Insider Trading
Date Person Action Amount type
2024-06-12 Ogden Christopher Buy 17 500 Common Stock
2024-06-12 Ogden Christopher Buy 75 000 Stock Option (Right to Buy)
2024-05-15 Young Matthew P. Buy 38 000 Stock Option (Right to Buy)
2024-05-15 Su Zhen Buy 38 000 Stock Option (Right to Buy)
2024-05-15 Mohindru Mani Buy 38 000 Stock Option (Right to Buy)
INSIDER POWER
67.89
Last 98 transactions
Buy: 4 522 928 | Sell: 1 092 240
Koreliacija (AI algo v.1.1b): Undervalued: 0.94% $1.393 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: 0.07 (neutral)
Trumpas: 0.56 (weak)
Signal:(57.449) Neutral

CytomX Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
OZEM1
LOGC0.91
NALFX0.894
BWIN0.893
IIXIX0.892
RGSVX0.888
RGIVX0.888
ANTUX0.887
PGJZX0.883
INFR0.879
10 Labiausiai neigiamai susiję koreliacijos
PLTNU-0.886
LDWY-0.847
AAPD-0.83
BRLSW-0.828
CGON-0.818
PXMD-0.812

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

CytomX Therapeutics Inc Koreliacija - Valiuta/Žaliavos

The country flag 0.64
( weak )
The country flag 0.45
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.68
( moderate negative )

CytomX Therapeutics Inc Finansinės ataskaitos

Annual 2023
Pajamos: $101.21M
Bruto pelnas: $99.04M (97.85 %)
EPS: $-0.00770
FY 2023
Pajamos: $101.21M
Bruto pelnas: $99.04M (97.85 %)
EPS: $-0.00770
FY 2022
Pajamos: $53.16M
Bruto pelnas: $47.31M (88.98 %)
EPS: $-1.480
FY 2021
Pajamos: $69.57M
Bruto pelnas: $69.57M (100.00 %)
EPS: $-1.300

Financial Reports:

CytomX Therapeutics Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.

Total Execution Time: 2.1206710338593 seconds
Number of API calls: 3
Number of DB calls: 9